Russell-Smith, T. Alexander http://orcid.org/0000-0003-1445-8138
Brockbank, James
Mamolo, Carla
Knight, Christopher
Funding for this research was provided by:
Pfizer
Article History
Accepted: 31 May 2021
First Online: 28 June 2021
Declarations
:
: This study was conducted by RTI Health Solutions (RTI-HS) under the direction of Pfizer Inc and was funded by Pfizer Inc. The authors wish to thank Dr. Hervé Dombret and Dr. Sylvie Castaigne for their expertise on the ALFA-0701 study and AML; Ingress-Health for performing survival analyses of the ALFA-0701 study data; and the clinical, statistical, and health economics experts who provided input into the model assumptions, design, and validation (Professor Nigel Russell, Professor Richard Clark, Dr. Paul Cahalin, Dr. Dominic Culligan, Dr. Sahra Ali, Dr. Priyanka Mehta, Dr. Victoria Potter, Professor Robert Hills, Professor Alan Brennan, Dr Nicholas Latimer, and Dr Praveen Thokala).
: Alexander Russell-Smith and Carla Mamolo are paid employees of Pfizer Inc, USA. James Brockbank and Christopher Knight are employees of RTI-HS, who were paid consultants to Pfizer in connection with the development of this manuscript.
: The authors confirm that the key data supporting the findings of this study are available within the article and its supplementary materials. Additional data are available from the corresponding author, Alexander Russell-Smith, upon reasonable request.
: All authors contributed to the study conception and design. Material preparation, non-clinical data collection and analysis were performed by JB and CK. The first draft of the manuscript was written by JB and CK, and all authors commented on previous versions of the manuscript. All authors reviewed and approved the final manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.